RESUMEN
OBJECTIVE: To observe the effect of furazolidone quadruple regimen plus dental plaque removal procedures as rescue treatment of refractory H. pylori infection. METHODS: A total of 104 patients with H. pylori positive [(13)C-urea breath test (UBT) or rapid urease test positive] failing in previous treatment two or more were enrolled and divided into 2 groups. One group (n = 64) were given quadruple regimen [proton pump inhibitor (PPI) + bismuth + amoxicillin + furazolidone, 10 days] treatment and dental plaque removal treatment. And the others (n = 40) received only quadruple regimen treatment. The status of H. pylori was detected by (13)C-UBT at 4 weeks post-therapy and the eradication rates of two groups were compared. RESULTS: The eradication rate of quadruple regimen + dental treatment group was 85.9% (55/64) while that of the other group 72.5% (29/40) (P = 0.091). CONCLUSION: The PPI + bismuth quadruple regimen plus dental plaque removal procedures as rescue treatment may boost the eradication rate of refractory H. pylori infection patients. And the furazolidone quadruple therapy can be chosen for the treatment of refractory H. pylori infection. Oral H. pylori infection may play a role in the failure of H. pylori infection treatment.
Asunto(s)
Antibacterianos/uso terapéutico , Placa Dental/microbiología , Placa Dental/terapia , Furazolidona/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Adolescente , Adulto , Anciano , Amoxicilina/uso terapéutico , Antiácidos/uso terapéutico , Antiulcerosos/uso terapéutico , Bismuto/uso terapéutico , Quimioterapia Combinada , Femenino , Furazolidona/administración & dosificación , Helicobacter pylori/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Insuficiencia del Tratamiento , Adulto JovenRESUMEN
Furazolidone has proven to have antiprotozoal and antibacterial activity. A number of literature supported its use against Helicobacter pylori. This potential application opens new prospects of its use in clinical settings in triple therapy. In order to avoid side effects associated with this drug, liposomal mucoadhesive drug delivery that can work locally in stomach is considered as an appropriate approach. This study is a focus on formulations and in vitro characterization of liposomes containing furazolidone. Therefore, the effects of variable amounts of drug and cholesterol on encapsulation efficacy and in vitro drug release were evaluated for different liposomal formulations. Mucoadhesive behavior of chitosan coated liposomal at two different pHs was also evaluated and increase in pH from 1.3 to 4.5 increased mucoadhesion from 42% to 60% respectively. Increasing the amount of drug from 4mg to 5mg increased encapsulation activity however, increasing the drug any further decreased encapsulation activity. In contrast, by increasing the amount of cholesterol decrease in encapsulation activity was observed. The optimized formulation with 5mg of drug and 53mg of cholesterol in formulation gave 57% drug release at pH 1.3 but release was increased up to 71% by increasing pH to 4.5 for same amount of drug. However, by using 10.6mg of cholesterol and 5mg of drug the overall release was increased at both pH conditions, at pH 1.3 release was 69% as compared to 77% at pH 4.5. This trend of drug release profile and mucoadhesion that favors pH 4.5 is documented as useful in targeting H. pylori as normal pH of stomach is expected to be higher by the influence of this microbe. Hence, the results of this research can be taken further into a future in vivo study.
Asunto(s)
Antibacterianos/química , Antiprotozoarios/química , Furazolidona/química , Animales , Antibacterianos/administración & dosificación , Antiprotozoarios/administración & dosificación , Química Farmacéutica , Quitosano/administración & dosificación , Quitosano/química , Colesterol/administración & dosificación , Colesterol/química , Sistemas de Liberación de Medicamentos , Liberación de Fármacos , Furazolidona/administración & dosificación , Mucosa Gástrica/metabolismo , Concentración de Iones de Hidrógeno , Liposomas , OvinosRESUMEN
The response of connective tissue on drugs with different action spectra (gentamycin, furazolidon, mefenamin sodium) immobilized on the poliurethane basis was studied experimentally. Immobilized forms of the drugs created favorable conditions for faster wound cicatrization.
Asunto(s)
Mucosa Bucal/efectos de los fármacos , Animales , Tejido Conectivo/efectos de los fármacos , Tejido Conectivo/patología , Preparaciones de Acción Retardada , Portadores de Fármacos , Implantes de Medicamentos , Furazolidona/administración & dosificación , Gentamicinas/administración & dosificación , Mucosa Bucal/patología , Orfenadrina/administración & dosificación , Poliuretanos , Conejos , Ratas , Cicatrización de Heridas/efectos de los fármacosRESUMEN
Drug delivery systems are promising pharmaceutical formulations used to improve the therapeutic index of drugs. In this study, we developed a liposomal formulation of furazolidone that targets Leishmania (Leishmania) chagasi amastigotes in a hamster model. Using laser scanning confocal microscopy, it was demonstrated that the liposomal drug co-localised with L. (L.) chagasi amastigotes within macrophages. Liposomal furazolidone administered intraperitoneally at 0.5mg/kg for 12 consecutive days reduced spleen (74%) and liver (32%) parasite burden at a 100-fold lower dose than the free drug. Free furazolidone (50mg/kg) also effectively reduced spleen (82.5%) and liver (85%) parasites; its in vitro activity against promastigotes and intracellular amastigotes demonstrated a high degree of parasite selectivity. Thus, furazolidone, both in the free and liposome-loaded formulation, is an effective inhibitor of L. (L.) chagasi, representing a possible cost-effective drug candidate for the treatment of visceral leishmaniasis.